## SDGR: Schrodinger, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($15.54)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. BofA Securities upgrades Schrodinger stock rating to Buy from Neutral By Investing.com**
- Source: Investing.com Nigeria | 20251216T110920 | Bullish | Relevance: 100%
- BofA Securities upgraded Schrodinger (NASDAQ:SDGR) from Neutral to Buy, citing the company's refocus on its software operations. This strategic shift, along with impressive revenue growth and positive Q3 2025 earnings, has led to a "cleaner story" and a more optimistic outlook for the $1.33 billion market cap company. KeyBanc also reiterated its Overweight rating.

**2. Schrodinger (NASDAQ:SDGR) Shares Gap Up After Analyst Upgrade**
- Source: MarketBeat | 20251216T110920 | Somewhat-Bullish | Relevance: 100%
- Shares of Schrodinger (NASDAQ:SDGR) gapped up after Bank of America upgraded the stock from neutral to buy, setting a $24 price target. This follows Schrodinger beating Q3 estimates with ($0.45) EPS versus a ($0.72) consensus and $54.32 million in revenue. Despite recent insider sales and continued unprofitability, analysts maintain a "Hold" rating with a consensus price target of $25.71.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $24 | $24 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-2.2%)
- Gates Foundation Tru: 10.8% (0.0%)
- Vanguard Group Inc: 9.8% (-4.2%)
- Rubric Capital Manag: 8.2% (+5.4%)
- Sumitomo Mitsui Trus: 7.1% (+24.8%)

### Key Risks

1. High short interest (25.5%, 10.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 17.3% below SMA200.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Balance sheet: strong liquidity (3.2x). Revenue growth strong at 20% YoY. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 1.57 |
| 52W Range | $15.99 - $28.47 |
| Short Interest | 25.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 3.1% to -1.2% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.83x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.17% (CS: 29) | Neutral |
| RSI_14 | 41.6 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.913x | Below |
| vs SMA200 | 0.827x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $17.20
- **Stop Loss:** $15.54 (9.7% risk)
- **Target:** $18.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 572
- **Position Value:** $9,838.40
- **Portfolio %:** 9.84%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.74 | $-0.57 | +23.0% |
| 2025Q2 | $-0.64 | $-0.65 | -1.6% |
| 2025Q1 | $-0.81 | $-0.64 | +21.0% |
| 2024Q4 | $-0.38 | $-0.24 | +36.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*